The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $9.00

Today's change0.00 0.00%
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $9.00

Today's change0.00 0.00%
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc closed at (U.S.)$9.00.

Over the last five days, shares have gained 1.81% and 31.00% year to date. Shares have outperformed the S&P 500 by 30.24% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $9.00
  • High--
  • Low--
  • Bid / Ask(U.S.) $8.95 / (U.S.) $9.10
  • YTD % change+31.00%
  • Volume0
  • Average volume (10-day)3,032,935
  • Average volume (1-month)4,850,465
  • Average volume (3-month)5,196,379
  • 52-week range(U.S.) $4.90 to (U.S.) $9.89
  • Beta1.58
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.88
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-140.67%

Although this company's net profit margin is negative, it is above the industry average and implies that ARIAD Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.02%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue24671512
Total other revenue--------
Total revenue24671512
Gross profit23661410
Total cost of revenue1112
Total operating expense74746268
Selling / general / administrative34403434
Research & development39332832
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-50-7-47-56
Interest income (expense), net non-operating-4-4-4-1
Gain (loss) on sale of assets--------
Other--------
Income before tax-52-6-50-57
Income after tax-53-6-50-57
Income tax, total0000
Net income-53-6-50-57
Total adjustments to net income--------
Net income before extra. items-53-6-50-57
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-53-6-50-57
Inc. avail. to common incl. extra. items-53-6-50-57
Diluted net income-53-6-50-57
Dilution adjustment----00
Diluted weighted average shares188187187187
Diluted EPS excluding extraordinary itemsvalue per share-0.28-0.03-0.27-0.30
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.28-0.03-0.27-0.30